drugset / Trial / NCT01930240
The Safety of a Hypolipidemic Agent in Healthy Normal Volunteers
RandomizedCrossoverDouble-blind
Summary
The primary objective of the study is to assess the blood profile of the N-methylnicotinamide (MNA) following administration of TRIA-662 (N-methylnicotinamide Chloride). The secondary objectives of the study are to characterize the safety and tolerability of TRIA-662 and to assess any potential gender-related differences in the plasma profile of MNA. Changes in serum lipid parameters with particular reference to triglycerides, lipoprotein lipase, and blood pressure effects will also be noted.
Timeline
- Start
- 2007-11
- Primary completion
- 2008-01
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TRIGONELLAMIDE | Small molecule | 90 mg | Oral |
| Subject | TRIGONELLAMIDE | Small molecule | 270 mg | Oral |
Indications
No indication recorded.